Revance Therapeutics Inc (RVNC)

[jmkobers]

Dew:

Regarding the price to market for the multiple therapeutic indications currently awaiting or just starting phase 2 trials: can each of these re-use the > 2000 patient safety database recently completed for aesthetics, or would each individual therapeutic indication need its own safety database similar in size to one completed for aesthetics?

I am assuming re-use and that relatively small (200-500) person studies would be acceptable for each of the therapeutic indications for approval. If not, the costs left on the table for approval of the full suite of products currently under development would seem to be mind-boggling.